What is Fragile X (FX) syndrome?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 17, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Fragile X Syndrome Overview

Fragile X syndrome (FXS) is an X-linked genetic disorder caused by mutations in the FMR1 gene located at Xq27.3, representing the most common inherited cause of intellectual disability and a leading genetic cause of autism spectrum disorder. 1

Genetic Basis

The molecular defect involves CGG trinucleotide repeat expansion in the 5' untranslated region of the FMR1 gene:

  • Full mutation: >200 CGG repeats causes FXS through loss of fragile X mental retardation protein (FMRP) expression 1
  • Premutation: 55-200 CGG repeats causes carrier status with distinct clinical syndromes 1, 2
  • Normal range: <55 CGG repeats 1

The inheritance pattern is X-linked with multistep expansion occurring over generations, with the parent of origin for expansion to full mutation being female in virtually all cases 1

Clinical Manifestations in Full Mutation

Cognitive and Behavioral Features

Males with full mutations demonstrate complete penetrance for intellectual disability, while females show variable expression due to X-inactivation patterns: 3

  • Intellectual disability: Ranges from mild to severe, with males typically more severely affected than females 3, 2
  • Autism spectrum disorder: Occurs in approximately 20% of boys with FXS when evaluated by objective diagnostic criteria 3
  • Behavioral phenotype: Includes characteristic but nonspecific physical features and behaviors 1

Medical Complications

Associated medical problems requiring surveillance include:

  • Seizures: Develop in approximately 10-20% of individuals 3
  • Recurrent otitis media and hearing difficulties: Necessitate audiologic assessment 3
  • Ophthalmologic problems: Strabismus and refractive errors require evaluation 3

Premutation-Associated Conditions

Fragile X-Associated Primary Ovarian Insufficiency (FXPOI)

Females with premutations, particularly those with >80 CGG repeats, face approximately 20% risk for premature ovarian insufficiency. 1, 3 Importantly, there is no evidence supporting an association between high normal and intermediate range FMR1 alleles with POI risk 1

Fragile X-Associated Tremor/Ataxia Syndrome (FXTAS)

FXTAS represents a late-onset, progressive neurodegenerative disorder affecting older males and females with premutations: 1, 3

  • Core features: Intention tremor and ataxia accompanied by progressive cognitive and behavioral difficulties including memory loss, anxiety, reclusive behavior, executive function deficits, and dementia 1
  • Risk factors: Higher in males carrying premutations compared to females, with penetrance increasing with age and premutation repeat length 1, 3
  • Typical onset: Males over age 50 3

Premutation Cognitive Effects

Most individuals with premutations do not show FXS-related features; however, some with high repeat sizes (>100 repeats) may present with learning difficulties, emotional problems, or intellectual disability. 1, 3

Molecular Pathophysiology

FMRP functions as an RNA-binding protein and translation suppressor that regulates protein synthesis locally in dendrites in response to synaptic stimulation. 1 The absence of FMRP in FXS leads to exaggerated translation of certain messages, resulting in abnormally long and thin dendritic spines in cortical regions where excitatory synaptic transmission occurs 1

Diagnostic Considerations

The OMIM numbers for clinical reference are: *309550 (FMR1 gene), 300624 (fragile X mental retardation syndrome including FXPOI), and 300623 (FXTAS) 1

Molecular genetic testing of the FMR1 gene is one of the most frequently ordered genetic tests, requiring Southern blot analysis and polymerase chain reaction amplification methods including triplet repeat-primed and methylation-specific PCR. 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Clinical Presentation of Fragile X Syndrome

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.